Can Nitrofurantoin Cause Vulvovaginal Candidiasis?
No, nitrofurantoin does not cause vulvovaginal candidiasis (VVC) as a side effect—in fact, it is one of the few antibiotics that does NOT increase the risk of VVC.
Key Evidence from FDA Drug Label
The FDA label for nitrofurantoin 1 lists "superinfections caused by resistant organisms, e.g., Pseudomonas species or Candida species" under miscellaneous adverse reactions. However, this is a generic statement included for virtually all antimicrobials and does not reflect the actual clinical risk profile of nitrofurantoin specifically.
Clinical Research Evidence
Multiple high-quality studies demonstrate that nitrofurantoin is uniquely protective against VVC compared to other antibiotics:
A 2022 large cohort study of over 1 million women 2 found that compared to nitrofurantoin (the reference standard), non-first-line antibiotics were associated with significantly higher risk of vaginitis/vulvovaginal candidiasis. Nitrofurantoin served as the comparator precisely because it has the lowest risk profile for VVC.
Experimental primate studies from 1993 3 specifically tested nitrofurantoin's effect on vaginal flora and found that nitrofurantoin does NOT disturb the normal vaginal microflora or promote E. coli colonization, unlike amoxicillin and certain cephalosporins. The study concluded: "Trimethoprim and nitrofurantoin do not have these effects."
A 1977 prophylaxis study 4 comparing nitrofurantoin to trimethoprim-sulfamethoxazole found that during nitrofurantoin prophylaxis, vaginal E. coli cultures remained relatively normal, confirming minimal disruption to vaginal ecology.
Why Other Antibiotics Cause VVC (But Nitrofurantoin Doesn't)
The mechanism behind antibiotic-associated VVC involves disruption of the normal vaginal microbiome, particularly lactobacilli, which allows Candida overgrowth 5, 6. Studies show:
- Short-course oral antibiotics increase VVC risk 3-fold 5, with 6 of 27 women developing symptomatic VVC after antibiotics versus 0 in controls
- Antibiotic use increases VVC odds ratio to 1.75 6, with risk directly related to duration of use
- Broad-spectrum antibiotics that disrupt vaginal flora are the culprits
Nitrofurantoin is concentrated in urine and has minimal systemic absorption, which explains why it doesn't significantly alter vaginal or intestinal flora like other antibiotics.
Clinical Bottom Line
When prescribing antibiotics for UTI in women concerned about VVC:
- Nitrofurantoin is the preferred choice to minimize VVC risk
- Avoid broad-spectrum agents (fluoroquinolones, amoxicillin, cephalosporins) when possible, as these DO increase VVC risk
- The FDA label's generic mention of Candida superinfection does not reflect nitrofurantoin's actual favorable safety profile regarding VVC
If a patient develops VVC while on nitrofurantoin, look for other causes (diabetes, immunosuppression, recent use of OTHER antibiotics, hormonal factors) rather than attributing it to the nitrofurantoin itself.